Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.
Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.
复制标题
血液透析对尿毒症患者癌胚抗原、甲胎蛋白、鳞癌相关抗原、神经元特异性烯醇化酶、CA 125、CA 19-9、CA 15-3 7 种肿瘤标志物浓度的影响
DOI：
10.1159/000168339
复制
发表时间：
1991
影响因子：
4.2
通讯作者：
T. Nomura
中科院分区：
文献类型：
--
作者：
E. Odagiri;K. Jibiki;M. Takeda;H. Sugimura;C. Iwachika;Y. Abe;K. Kihara;Y. Kihara;M. Itou;T. Nomura
本文对144例无恶性肿瘤的尿毒症患者血液透析前后癌胚抗原（CEA）、甲胎蛋白（AFP）、鳞状细胞癌相关抗原（SCC）、神经元特异性烯醇化酶（NSE）、CA 125、CA 19-9和CA 15-3等7项肿瘤标志物的变化进行了研究。HD前，所有肿瘤标志物中，仅SCC的平均浓度超过正常值。癌胚抗原（CEA）和神经元特异性烯醇化酶（NSE）的阳性率分别为25.7%和10.6%。然而，所有病例的AFP均在正常范围内。CA抗原中，CA 125阳性率为7.6%，CA 19-9阳性率为6.3%，CA 15-3阳性率为3.5%。HD后，所有肿瘤标志物的发生率和平均浓度均升高。HD后总蛋白水平平行增加。HD中使用的膜滤器似乎不足以在HD期间清除肿瘤标志物蛋白。有必要考虑尿毒症患者肿瘤标志物升高的临床解释。
The incidence of the 7 tumor markers carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), squamous cell carcinoma-related antigen (SCC), neuron-specific enolase (NSE), CA 125, CA 19-9 and CA 15-3 was studied before and after hemodialysis (HD) in 144 uremic patients who had no malignancies. Before HD, of all tumor markers, the mean concentration of SCC only exceeded the normal value. The positive rate was highest in SCC (95.1%), and that of CEA and NSE was 25.7 and 10.6%, respectively. However, AFP was within the normal range in all cases. Among CA antigens, the positive rate of CA 125 was 7.6%, of CA 19-9 was 6.3% and of CA 15-3 was 3.5%. After HD, the incidence as well as the mean concentration of all tumor markers increased. A parallel increment of total protein was observed after HD. The membrane filter used in HD appears to be insufficient to remove tumor marker proteins during HD. It is necessary to consider the clinical interpretation of elevated tumor markers in patients with uremia.